Trademark Overview
On Wednesday, January 3, 2024, a trademark application was filed for SYNCAN with the United States Patent and Trademark Office. The USPTO has given the SYNCAN trademark a serial number of 98340018. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Wednesday, January 3, 2024. This trademark is owned by RADIUS PHARMACEUTICALS, INC.. The SYNCAN trademark is filed in the Pharmaceutical Products category with the following description:
Pharmaceutical preparation for the treatment of epilepsy, Prader-Willi syndrome, obesity, graft versus host disease, gelastic seizures and seizures related to hypothalamic hamartoma, neonatal seizures, movement disorders including dystonia, central pain syndromes, phantom limb pain, multiple sclerosis, traumatic brain injury, injury caused by radiation therapy, acute and chronic graft versus host disease, T-cell autoimmune disorders, colitis, Dravet Syndrome, Lennox Gastaut Syndrome, mycolonic seizures, juvenile mycolonic epilepsy, refractory epilepsy, schizophrenia, juvenile spasms, West syndrome, infantile spasms, refractory infantile spasms, tubular sclerosis complex, brain tumors, neuropathic pain, cannabis use disorder, post-traumatic stress disorder, anxiety, early psychosis, Alzheimer's Disease, autism, acne, Parkinson's disease, social anxiety disorder, depression, chemotherapy-induced peripheral neuropathy (CIPN), Rett syndrome, and withdrawal from opioids, cocaine, heroin, am...
